Lymphoma Trial, Recruiting NCT06895538 Sponsor: Peking University First Hospital Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT06895538
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender
  • People who have been diagnosed with a blood cancer or malignant blood disease, confirmed through laboratory testing of tissue or cell samples
  • People who have not previously had an allogeneic stem cell transplant (a transplant using cells from a donor)
  • People with a general health and activity level rated between 0 and 2 on a standard medical scale (meaning able to carry out daily activities with at most moderate limitations)
  • People whose kidney function, liver function, heart function, and blood oxygen levels fall within the specific acceptable ranges required by the trial (confirm with trial site for exact values)
  • People whose doctors expect them to survive for longer than 12 weeks
  • People who are willing to follow all study requirements and sign a consent form

Who may not be able to join:

  • People who have received certain immune-suppressing treatments known as ATG, ALG, or ATLG within the past six months
  • People who have a known allergy to any ingredient in the ATG or ATLG medications used in the trial
  • People who have an active bacterial, viral, parasitic, or mycobacterial infection that is not well-controlled with treatment, and which would prevent a stem cell transplant from going ahead
  • People who are pregnant or breastfeeding, or people who are capable of becoming pregnant but are unwilling or unable to use effective contraception during the trial
  • People who have participated in another clinical trial involving an experimental drug or device within the 30 days before their first trial visit (those in observational studies only may still be considered)
  • People where the treating doctor judges that any other condition or circumstance could interfere with the trial or its results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-13671375500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University First Hospital
Registry
ClinicalTrials.gov
Start date
3 May 2025
Est. completion
1 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of viral infections after hematopoietic stem cell transplantation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov